Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Lysyl oxidase-like 2 (LOXL2), a collagenmodifying enzyme, has been implicated in cancer invasiveness and metastasis. Methods: We evaluated the expression of LOXL2 protein, in addition to carbonic anhydrase IX (CAIX), keratin 19, epithelial cell adhesion molecule, and interleukin 6, in 105 resected hepatocellular carcinomas (HCCs) by immunohistochemistry. Results: LOXL2 positivity was found in 14.3% (15/105) of HCCs, and it was significantly associated with high serum α-fetoprotein levels, poor differentiation, fibrous stroma, portal vein invasion, and advanced TNM stage (p<0.05 for all). Additionally, LOXL2 positivity was significantly associated with CAIX (p=0.005) and stromal interleukin 6 expression (p=0.001). Survival analysis of 99 HCC patients revealed LOXL2 positivity to be a poor prognostic factor; its prognostic impact appeared in progressed HCCs. Furthermore, LOXL2 positivity was shown to be an independent predictor of overall survival and disease-specific survival (p<0.05 for all). Interestingly, co-expression of LOXL2 and CAIX was also an independent predictor for overall survival, disease-specific survival, disease-free survival, and extrahepatic recurrence-free survival (p<0.05 for all). Conclusions: LOXL2 expression represents a subgroup of HCCs with more aggressive behavior and is suggested to be a poor prognostic marker in HCC patients.
Abstract
Background/Aims: Lysyl oxidase-like 2 (LOXL2), a collagenmodifying enzyme, has been implicated in cancer invasiveness and metastasis. Methods: We evaluated the expression of LOXL2 protein, in addition to carbonic anhydrase IX (CAIX), keratin 19, epithelial cell adhesion molecule, and interleukin 6, in 105 resected hepatocellular carcinomas (HCCs) by immunohistochemistry. Results: LOXL2 positivity was found in 14.3% (15/105) of HCCs, and it was significantly associated with high serum α-fetoprotein levels, poor differentiation, fibrous stroma, portal vein invasion, and advanced TNM stage (p<0.05 for all). Additionally, LOXL2 positivity was significantly associated with CAIX (p=0.005) and stromal interleukin 6 expression (p=0.001). Survival analysis of 99 HCC patients revealed LOXL2 positivity to be a poor prognostic factor; its prognostic impact appeared in progressed HCCs. Furthermore, LOXL2 positivity was shown to be an independent predictor of overall survival and disease-specific survival (p<0.05 for all). Interestingly, co-expression of LOXL2 and CAIX was also an independent predictor for overall survival, disease-specific survival, disease-free survival, and extrahepatic recurrence-free survival (p<0.05 for all). Conclusions: LOXL2 expression represents a subgroup of HCCs with more aggressive behavior and is suggested to be a poor prognostic marker in HCC patients.
참고문헌 (39)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
- Yu SJ, "A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world : 2010-2016", Clin Mol Hepatol, 22, pp.7~17 (2016)
- Cox TR, "Remodeling and homeostasis of the extracellular matrix : implications for fibrotic diseases and cancer", Dis Model Mech, 4, pp.165~178 (2011)
- Lu P, "The extracellular matrix : a dynamic niche in cancer progression", J Cell Biol, 196, pp.395~406 (2012)
- Levental KR, "Matrix crosslinking forces tumor progression by enhancing integrin signaling", Cell, 139, pp.891~906 (2009)
- Butcher DT, "A tense situation : forcing tumour progression", Nat Rev Cancer, 9, pp.108~122 (2009)
- Schrader J, "Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells", Hepatology, 53, pp.1192~1205 (2011)
- Kim H, "Human hepatocellular carcinomas with"Stemness"-related marker expression : keratin 19 expression and a poor prognosis", Hepatology, 54, pp.1707~1717 (2011)
- Seok JY, "A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition", Hepatology, 55, pp.1776~1786 (2012)
- Barker HE, "The rationale for targeting the LOX family in cancer", Nat Rev Cancer, 12, pp.540~552 (2012)
- Xiao Q, "Lysyl oxidase, extracellular matrix remodeling and cancer metastasis", Cancer Microenviron, 5, pp.261~273 (2012)
- Wu L, "The function and mechanisms of action of LOXL2in cancer(review)", Int J Mol Med, 36, pp.1200~1204 (2015)
- Akiri G, "Lysyl oxidase-related protein-1promotes tumor fibrosis and tumor progression in vivo", Cancer Res, 63, pp.1657~1666 (2003)
- Kirschmann DA, "A molecular role for lysyl oxidase in breast cancer invasion", Cancer Res, 62, pp.4478~4483 (2002)
- Peinado H, "A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression", EMBO J, 24, pp.3446~3458 (2005)
- Peinado H, "Lysyl oxidaselike 2 as a new poor prognosis marker of squamous cell carcinomas", Cancer Res, 68, pp.4541~4550 (2008)
- Peng L, "Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src", FAK pathway, 2009, pp.30, 1660~1669
- Li TY, "Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma", Hum Pathol, 43, pp.1068~1076 (2012)
- Barry-Hamilton V, "Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment", Nat Med, 16, pp.1009~1017 (2010)
- Wong CC, "Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma", Hepatology, 60, pp.1645~1658 (2014)
- Nault JC, "A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection", Gastroenterology, 145, pp.176~187 (2013)
- Gilkes DM, "Hypoxia and the extracellular matrix : drivers of tumour metastasis", Nat Rev Cancer, 14, pp.430~439 (2014)
- Wong CC, "Inhibitors of hypoxiainducible factor 1 block breast cancer metastatic niche formation and lung metastasis", J Mol Med(Berl), 90, pp.803~815 (2012)
- Erler JT, "Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche", Cancer Cell, 15, pp.35~44 (2009)
- Schietke R, "The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia : insights into cellular transformation processes mediated by HIF-1", J Biol Chem, 285, pp.6658~6669 (2010)
- McDonald PC, "Carbonic anhydrase IX(CAIX)as a mediator of hypoxia-induced stress response in cancer cells", Subcell Biochem, 75, pp.255~269 (2014)
- Colpaert CG, "The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis", Breast Cancer Res Treat, 81, pp.137~147 (2003)
- Trastour C, "HIF-1alpha and CA IX staining in invasive breast carcinomas : prognosis and treatment outcome", Int J Cancer, 120, pp.1451~1458 (2007)
- Rhee H, "Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia : resistance to transarterial chemoembolization", Mod Pathol, 29, pp.1038~1049 (2016)
- Currie MJ, "Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ : relationships with markers of tumor hypoxia and microvascularity", Hum Pathol, 44, pp.402~411 (2013)
- Pez F, "The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth", Cancer Res, 71, pp.1647~1657 (2011)
- Kim H, "Hepatocellular carcinomas expressing ‘stemness’-related markers : clinicopathological characteristics", Dig Dis, 32, pp.778~785 (2014)
- Wang CQ, "Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression", Am J Cancer Res, 6, pp.1873~1889 (2016)
- Lin ZY, "Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells", Biomed Pharmacother, 66, pp.525~529 (2012)
- Kockar F, "Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro", World J Clin Oncol, 3, pp.82~91 (2012)
- Moreno-Bueno G, "Lysyl oxidase-like 2(LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas", EMBO Mol Med, 3, pp.528~544 (2011)
- Wu L, "The effect of LOXL2 in hepatocellular carcinoma", Mol Med Rep, 14, pp.1923~1932 (2016)